QQ客服 官方微博 反馈留言

	Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse
	Jia, Zhenyu1; Rahmatpanah, Farah B.1; Chen, Xin1; Lernhardt, Waldemar2; Wang, Yipeng3; Xia, Xiao-Qin4; Sawyers, Anne1; Sutton, Manuel1; McClelland, Michael1,5; Mercola, Dan1
刊名	PLOS ONE
	2012-08-01
卷号	7期号:8页码:e41371
关键词	GENE-EXPRESSION TUMOR MICROENVIRONMENT RADICAL PROSTATECTOMY ACTIVE SURVEILLANCE TIME DIAGNOSIS MARKER COHORT CELLS MEN
ISSN号	1932-6203
通讯作者	Jia, ZY (reprint author), Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92717 USA.
中文摘要	Biomarkers are needed to address overtreatment that occurs for the majority of prostate cancer patients that would not die of the disease but receive radical treatment. A possible barrier to biomarker discovery may be the polyclonal/multifocal nature of prostate tumors as well as cell-type heterogeneity between patient samples. Tumor-adjacent stroma (tumor microenvironment) is less affected by genetic alteration and might therefore yield more consistent biomarkers in response to tumor aggressiveness. To this end we compared Affymetrix gene expression profiles in stroma near tumor and identified a set of 115 probe sets for which the expression levels were significantly correlated with time-to-relapse. We also compared patients that chemically relapsed shortly after prostatectomy (<1 year), and patients that did not relapse in the first four years after prostatectomy. We identified 131 differentially expressed microarray probe sets between these two categories. 19 probe sets (15 genes overlapped between the two gene lists with p<0.0001). We developed a PAM-based classifier by training on samples containing stroma near tumor: 9 rapid relapse patient samples and 9 indolent patient samples. We then tested the classifier on 47 different samples, containing 90% or more stroma. The classifier predicted the risk status of patients with an average accuracy of 87%. This is the first general tumor microenvironment-based prognostic classifier. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.
英文摘要	Biomarkers are needed to address overtreatment that occurs for the majority of prostate cancer patients that would not die of the disease but receive radical treatment. A possible barrier to biomarker discovery may be the polyclonal/multifocal nature of prostate tumors as well as cell-type heterogeneity between patient samples. Tumor-adjacent stroma (tumor microenvironment) is less affected by genetic alteration and might therefore yield more consistent biomarkers in response to tumor aggressiveness. To this end we compared Affymetrix gene expression profiles in stroma near tumor and identified a set of 115 probe sets for which the expression levels were significantly correlated with time-to-relapse. We also compared patients that chemically relapsed shortly after prostatectomy (<1 year), and patients that did not relapse in the first four years after prostatectomy. We identified 131 differentially expressed microarray probe sets between these two categories. 19 probe sets (15 genes overlapped between the two gene lists with p<0.0001). We developed a PAM-based classifier by training on samples containing stroma near tumor: 9 rapid relapse patient samples and 9 indolent patient samples. We then tested the classifier on 47 different samples, containing 90% or more stroma. The classifier predicted the risk status of patients with an average accuracy of 87%. This is the first general tumor microenvironment-based prognostic classifier. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.
WOS标题词	Science & Technology
类目[WOS]	Multidisciplinary Sciences
研究领域[WOS]	Science & Technology - Other Topics
关键词[WOS]	GENE-EXPRESSION ; TUMOR MICROENVIRONMENT ; RADICAL PROSTATECTOMY ; ACTIVE SURVEILLANCE ; TIME ; DIAGNOSIS ; MARKER ; COHORT ; CELLS ; MEN
收录类别	SCI
资助信息	National Institutes of Health Strategic Partners for the Evaluation of Cancer Signatures (SPECS) Consortium [U01 CA1148102]; National Cancer Institute Early Detection Research Network (EDRN) Consortium [U01 CA152738]; University of California of Irvine Faculty Career Development Award; Chao Family Comprehensive Cancer Center at University of California of Irvine; Department of Defense Congressionally Directed Medical Research Programs [W81XWH-08-1-0720]; University of California of Irvine Institute for Cancer Research from the National Cancer Institute [T32CA009054]
语种	英语
WOS记录号	WOS:000307212800017
公开日期	2013-01-09
内容类型	期刊论文
源URL	[http://ir.ihb.ac.cn/handle/342005/17270]
专题	水生生物研究所_水生生物分子与细胞生物学研究中心_期刊论文
作者单位	1.Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92717 USA 2.Proveri, San Diego, CA USA 3.AltheaDx, San Diego, CA USA 4.Chinese Acad Sci, Dept Bioinformat, Inst Hydrobiol, Wuhan, Hubei, Peoples R China 5.Vaccine Res Inst San Diego, San Diego, CA USA
推荐引用方式 GB/T 7714	Jia, Zhenyu,Rahmatpanah, Farah B.,Chen, Xin,et al. Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse[J]. PLOS ONE,2012,7(8):e41371.
APA	Jia, Zhenyu.,Rahmatpanah, Farah B..,Chen, Xin.,Lernhardt, Waldemar.,Wang, Yipeng.,...&Mercola, Dan.(2012).Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse.PLOS ONE,7(8),e41371.
MLA	Jia, Zhenyu,et al."Expression Changes in the Stroma of Prostate Cancer Predict Subsequent Relapse".PLOS ONE 7.8(2012):e41371.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。